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Abstract
Purpose The aim of this study was to evaluate the effects of switching to ranibizumab in patients with neovascular age-related
macular degeneration (nAMD) refractory to aflibercept treatment and to identify predictive factors for switch response.
Methods A retrospective chart review was conducted including 32 eyes from 26 patients with refractory nAMD, who switched
from monthly intravitreal aflibercept treatment (≥ 6 months) to ranibizumab. Outcome measures included changes in visual
acuity (VA), intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and central retinal thickness
(CRT), evaluated at 6 months before switch (T1), at the time of switch (T2), and 3 months post-switch (T3).
Results There was an increase in CRT from T1 to T2, which decreased after switch from T2 to T3. Regression analysis of the
changes per month observed between time points showed significant differences in PED height (p = 0.02), SRF (p = 0.01), and
neuroretinal thickness as a measure for IRF (p = 0.03). No significant change was found for VA. Predictive factors for better
switch response included an exacerbation between T1 and T2, thicker measurements at T2, male sex, shorter treatment duration
before switch, and fewer preceding injections. No association with preceding switch was found.
Conclusion Patients with nAMD refractory to aflibercept benefit from switching to ranibizumab, particularly those whose
condition worsened prior to the switch. This may be explained by drug tolerance to aflibercept. Our findings may facilitate
making appropriate treatment decisions, potentially improving patient outcomes.
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Introduction
Age-related macular degeneration (AMD) is a frequent retinal
disorder in the elderly, which can lead to the loss of central
vision and legal blindness [1, 2]. Neovascular AMD (nAMD)
is a late form of AMD characterized by choroidal neovascu-
larization leading to macular exudation and ultimately fibrosis
with severe vision loss. Intravitreal anti-vascular endothelial
growth factor (anti-VEGF) agents have been found to improve
visual acuity (VA) outcomes in nAMD [3, 4]. Two anti-VEGF
drugs are most widely used based on their effectiveness and
FDA approval: ranibizumab, which was first commercialized
in 2006, and aflibercept, which has been available since 2011.
These two drugs differ from each other in terms of their struc-
ture and pharmacological action. Ranibizumab is a humanized
monoclonal antibody antigen-binding fragment that blocks
VEGF-A, whereas aflibercept is a soluble recombinant fusion
protein composed of VEGF receptors 1 and 2. Consequently,
in contrast to ranibizumab, aflibercept inhibits not only
VEGF-A but also VEGF-B and placental growth factor, all
of which are thought to be involved in nAMD pathology [5].
Aflibercept has a higher affinity and a longer activity than
ranibizumab, at least in theory [5–7]. However, both drugs
seem to have similar visual benefits when applied in nAMD
treatment [3].
Retreatment need of nAMD patients, which is necessary in
order to control for exudative recurrences, is highly variable
between affected individuals. While the mean need for
retreatment is approximately every 2 months, some patients
present with intraretinal fluid (IRF) and/or subretinal fluid
(SRF) despite the maximal dosage of monthly retreatment
[3]. These patients are commonly referred to as refractory to
the respective drug, although this does not imply an absence
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of but rather an insufficiency of treatment effect [8]. Drug
tolerance, among others, has been suggested as a possible
reason for refractoriness [9]. Improvement of the structural
response has been extensively reported after drug switch from
ranibizumab to aflibercept [10–17]. Whether the effectiveness
of this drug switch is attributable to a circumvention of drug
tolerance or the different pharmacologic behaviors of the
drugs has been speculated. However, there is little evidence
about the effect of switching from aflibercept to ranibizumab
[18–20]. Such evidence could help to elucidate the role of
drug tolerance versus pharmacological differences. In addi-
tion, it would be helpful for making appropriate and individual
clinical decisions.
The aim of this study was to evaluate the effects of
switching from aflibercept to ranibizumab in patients with
refractory nAMD and to identify potential predictive
factors.
Methods
This study was a retrospective chart review performed at the
medical retina unit of the Jules Gonin University Eye Hospital
in Lausanne, Switzerland. The study was approved by the
Swiss Federal Department of Health for retrospective data
analysis and was performed in accordance with the ethical
standards of the Declaration of Helsinki. This study did not
require informed consent.
A consecutive series of patients with nAMD, refractory to
monthly anti-VEGF therapy using aflibercept, and having
switched to ranibizumab were identified from the institutional
database. Refractoriness was defined as evidence of IRF or
SRF on spectral domain optical coherence tomography (SD-
OCT) at each monthly visit for 6 months or more, despite
monthly aflibercept injection. Exclusion criteria were the pres-
ence of any retinal pathology other than nAMD, poor OCT
image quality, and interruption of treatment.
The routine treatment protocol comprised a series of 3
monthly injections, which, if fluid was still present, was re-
peated. If nAMD showed refractoriness despite treatment on-
going for at least 12 months, anti-VEGF switch was consid-
ered. The choice of the first anti-VEGF used was not guided
by any clinical ocular parameter. Clinicians tended to use first
ranibizumab due to its ease of preloaded syringes. However,
during the year 2013, we recruited treatment naïve patients for
a 2-year study using aflibercept in 112 eyes [21]. In case of
refractoriness at the end of this study, they were typically
switched to ranibizumab. After switching to ranibizumab, pa-
tients went through another series of 3 monthly injections. If a
dry macula was achieved at the end of this regimen, injection
intervals were extended thereafter from 1 to 1.5 months ac-
cording to the observe and plan regiment [21–23].
For each included patient and eye, the following data were
collected: best available VA, routinely measured on the Early
Treatment Diabetic Retinopathy Study (ETDRS) chart; pres-
ence or absence of IRF and SRF on SD-OCT; the respective
maximal thickness on the vertical A-scan; presence or absence
of pigment epithelial detachment (PED) and its maximum
height; and the central retinal thickness (CRT) as measured
by the integrated software of the OCT Spectralis device
(Heidelberg Engineering, Dossenheim, Germany). Each of
the above parameters was evaluated at three different time
points. The T1 time corresponded to 6 months before switch.
The T2 time corresponded to the time of the drug switch, and
T3 time was 3 months after switch. Further, collected data
included age, sex, eye, date of initiation of aflibercept treat-
ment, number of injections received in the study eye, and
previous anti-VEGF switches.
Outcome measures were changes in VA, CRT, dryness of
the macula, SRF height, and PED height. Variables analyzed
for their impact on these outcome measures included the cor-
responding change during the 6 months preceding the switch,
the absolute value at T2, age, sex, number of previous injec-
tions, previous switch, and the duration of aflibercept
treatment.
The statistical analysis included descriptive statistics and a
paired analysis of continuous variables to identify significant
changes over time. An association analysis was performed to
identify factors associated with the structural outcome mea-
sures after switch, using Pearson’s correlation analysis for
continuous variables and ANOVA for categorical variables.
The JMP statistical program for Windows (version 8.0.1,
SAS institute Inc., Cary, NC) was used. Data are expressed
as mean ± standard deviation (SD). P < 0.05 was considered
statistically significant.
Results
The inclusion criteria were met by 32 eyes (19 right and 13
left eyes) from 26 patients with a mean age of 75.5 ±
7.8 years, 18 of which were female (69%). The proportion
of occult subtype was 30 out of 32 eyes (93.8%). Classic
neovascularization was present in one and angiomatous
proliferation in one eye. Patients received an average of
34.5 ± 13.4 intravitreal injections of anti-VEGF over 3.5
± 1.4 years. Sixteen eyes (50%) had already been previous-
ly switched (from ranibizumab to aflibercept). The preced-
ing switch (from ranibizumab to aflibercept) in these 50%
of cases had been performed with a mean of 17.4 months
(SD 9.8, range 7.2 to 39.7 months) before the investigated
switch. The number of injections (aflibercept) given be-
tween the first and the second switch was 16.4 (SD 8.7,
range 7 to 39).
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Comparison between time points
Table 1 summarizes the means and SDs of VA, CRT,
PED, and SRF with corresponding p values, and the num-
ber of eyes with presence or absence of IRF, at the differ-
ent time points (T1, T2, T3). While CRT, SRF, and PED
increased from T1 to T2, the opposite was found between
T2 and T3. These differences only partially reached sta-
tistical significance (Table 1). However, the comparison
between T1 and T3 was not significantly different. VA
decreased slightly, both from T1 to T2 and from T2 to
T3. The VA change reached significance when comparing
T1 with T3.
The presence of IRF changed very little between time
points (only 1 case with new IRF from T1 to T2, Table 1),
while SRF showed more fluctuation with a clear increase
from T1 (18 eyes) to T2 (24 eyes) and a decrease from T2
to T3 (19 eyes). Complete dryness, i.e., the absence of
IRF and SRF, was achieved in 4 eyes (13%) at T3.
Regression analysis of the changes before and
after switch (slope)
As there was a clear effect switch on the evolution of
exudative signs before and after drug switch, we com-
pared not only the individual time points but also the
individual regression coefficients (slopes) before and after
switch. Paired analysis revealed statistically significant
changes: The slope (regression coefficient) of PED
changed significantly from increase (from T1 to T2) to a
decrease (T2 to T3) (p = 0.02), as did the slope of SRF
(p = 0.01) and neuroretinal thickness with IRF (p = 0.03).
No significant changes in regression coefficients were
found for CRT or VA.
Factor analysis related to the changes after switch
A number of candidate factors that were identified to possibly
be associated with the degree of change following drug switch
were analyzed using univariate and multivariate analysis. The
results are summarized in Table 2.
We found a significant association for all 4 outcome mea-
sures, i.e., CRT, IRF, SRF, and PED, between the changes
observed before (T1 to T2) and after the switch (T2 to T3).
This finding was confirmed in multivariate analysis for the
outcomes of CRT, SRF, and PED, indicating that a greater
increase prior to the switch predicted a greater decrease there-
after. Similarly, an association was seen for the changes in IRF
and SRF after switch with the corresponding absolute thick-
nesses at T2, suggesting that the more pathological fluid was
present, the better the eye responded to the switch in drugs.
Furthermore, the PED response post-switch was associated
with sex, in that male patients showed a stronger response
than female patients did. A shorter pre-switch treatment period
was associated with a better response to switch in SRF and
CRT, which was confirmed by multivariate analysis.
However, other candidate factors, such as age, the number
of injections received prior to switch, or having changed anti-
VEGF drugs before, were not confirmed as predictors for the
switch response from aflibercept to ranibizumab, except for
the change in SRF, which correlated with the number of pre-
ceding injections.
Discussion
In this retrospective study, we observed a promising response
to ranibizumab treatment in the eyes with nAMD that had
been refractory tomonthly aflibercept. However, this response
was found to be dependent on several specific factors, with a
Table 1 Visual and anatomical measurements at the different time points
Outcome measure T1 T2 T3
Mean ± SD Mean ± SD p value compared
with T1




VA in ETDRS letters 74.9 ± 12.8 72.3 ± 14.2 0.20 72.0 ± 13.5 0.85 0.07
CRT in μm thickness 379 ± 126 404 ± 109 0.13 393 ± 136 0.48 0.12
PED in μm height 234 ± 113 243 ± 111 0.16 226 ± 105 0.03 0.20
SRF in μm height 40 ± 44 78 ± 78 0.03 55 ± 77 0.06 0.71
T1
Number of eyes (%)
T2
Number of eyes (%)
T3
Number of eyes (%)
Presence of IRF 17 (53%) 18 (56%) 18 (56%)
Presence of SRF 18 (56%) 24 (75%) 19 (59%)
Statistical test, paired t test
VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; CRT, central retinal thickness; PED, pigment epithelial detachment; SRF,
subretinal fluid; SD, standard deviation; T1, 6 months before the switch; T2, switch time point; T3, 3 months post-switch
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particularly strong impact of the degree of change before
switch.
Similar to what has previously been reported for switching
from ranibizumab to aflibercept [10–17], we found that the
inverse switch can be effective in the treatment of nAMD as
well. Therefore, at least part of the effect of switch may not be
attributable to differences in drugs but rather a phenomenon
such as drug tolerance [8, 9, 24]. Tolerance occurs when the
response to a specific drug (aflibercept in this study) decreases
after repeated intravitreal injections, possibly because of com-
pensatory mechanisms. Such changes could include an in-
creased expression of VEGF or VEGF receptors, secretion
of other growth factors, interference of specific antibodies,
or changes in signal transduction [25]. Typically, it becomes
necessary to increase the anti-VEGF dosage or decrease the
treatment interval to maintain the same effect as achieved at
the beginning of the treatment [8]. The alternative explanation
by tachyphylaxis appears not applicable in nAMD, as it would
correspond to a rapid decrease in treatment effectiveness,
which cannot be improved by drug dosage, but only by tem-
porarily stopping treatment or increasing the interval between
the intravitreal injections. This mechanism could typically oc-
cur in drugs releasing neurotransmitters [8].
In the current study, VA did not improve following the
switch to ranibizumab, a finding consistent with many other
studies on switching anti-VEGF drugs that have shown a ben-
eficial response only in morphological parameters [10–12, 14,
16, 17, 20]. However, a few other groups did observe an
improvement of VA after switching drugs [13, 15, 18].
Although the ultimate goal of clinical eye research remains
visual function, improving structural aspects of the retina
remains useful even in the absence of immediate effects on
vision. Indeed, with prolonged duration of abnormal structural
changes, functional limitations tend to become increasingly
irreversible. Therefore, the attempt to achieve a retinal status
closest possible to normal anatomy appears justified even
without immediate visual effects. The absence of instanta-
neous changes in best corrected VA despite an observation
of molecular and structural changes could be related to previ-
ous irreversible retinal damage [26]. No ocular adverse events,
which could have distorted the functional results, have been
observed in this study.
We found that switching from aflibercept to ranibizumab
led to beneficial short-term results regarding retinal structure.
Previous reports about switchback from aflibercept to
ranibizumab have found similar results [18–20]. Compared
with the monthly change before the switch, PED, IRF, and
SRF showed significantly different, favorable changes post-
switch.
Novel findings of our study include the factors predicting
the observed post-switch changes, which could be of great
importance in clinical practice. The pre-switch structural
changes under aflibercept negatively correlated with the
post-switch response in morphological improvements to
ranibizumab. This was true for all structural outcomes, i.e.,
CRT, IRF, SRF, and PED, and was consistent with our previ-
ous study, in which we examined the effects of a switch from
ranibizumab to aflibercept for the treatment of nAMD [9].
Thus, evaluation of the pre-switch refractory treatment period,
independent of which anti-VEGF drug is used, may be useful
to identify which eyes are likely to benefit from a switch to
another anti-VEGF agent. Furthermore, the absolute values of
Table 2 Univariate and multivariate factor analysis related to the changes after switch

















R2 p value p value R2 p
value
p value R2 p
value
p value R2 p
value
p value
T1-T2 − 0.69 < 0.0001 0.001 − 0.39 0.03 NS − 0.54 0.001 0.0001 − 0.63 0.0001 0.0007
Absolute value
at T2
− 0.15 0.36 − 0.44 0.01 NS − 0.37 0.04 NS − 0.31 0.08 NS
Age − 0.24 0.14 NS 0.03 0.86 0.12 0.50 0.00 0.99
Sex 0.17 NS 0.07 NS 0.52 0.01 0.04
Injections
number
0.15 0.35 0.09 0.62 0.52 0.002 NS 0.06 0.76
Years before
switch
0.30 0.07 0.03 0.01 0.96 0.62 0.0002 0.0001 − 0.05 0.79
Preceding
switch
0.62 0.72 0.10 NS 0.87
Statistical tests, Pearson correlation analysis for continuous variables and ANOVA test for categorical variables
CRT, central retinal thickness; IRF, intraretinal fluid; SRF, subretinal fluid; PED, pigment epithelial detachment; R2 , correlation coefficient; NS, not
significant
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IRF and SRF at the time point of switch predicted the degree
of response to switching to ranibizumab.
An additional predictive factor we identified was the dura-
tion of the aflibercept treatment before the switch to
ranibizumab. It was an independent predictor for SRF and
CRT, whereby the shorter the eyes had been treated with
aflibercept, the better was their response to the new drug.
While the reasons behind this observation are not clear, it
could be speculated that chronicity of treatment reduces the
structural reactivity, perhaps due to protein-rich fluids.
Therefore, a new therapeutic strategy may involve brief treat-
ment periods with a successive switch to another, related drug.
Surprisingly, also sex was found to be a predictive factor,
whereby being male predicted the post-switch change, even
though this was restricted to PED. To the best of our knowl-
edge, no previous studies have identified sex as a factor
influencing the response to the switch from one anti-VEGF
drug to another. It is possible that the likelihood for the devel-
opment of a tolerance toward aflibercept is related to sex,
perhaps due to the anti-placental growth factor component
of the drug, whereby women might show less immunogenic-
ity to this component.
Limitations of the present study are the retrospective
nature of its design and the short follow-up period. A
longer observation would be necessary in order to evalu-
ate potential long-term functional effects. The high per-
centage of occult neovascularization may confine the con-
clusions mainly to this subtype. In addition, the sample
size was small, and CRT measures were not manually
corrected for segmentation errors.
In conclusion, the current study revealed encouraging re-
sults regarding structural aspects of refractory nAMD eyes
following the switch from aflibercept to ranibizumab.
Several factors were identified to predict which eyes benefit
most from such a treatment change. In addition to retinal
thickness, a particularly strong predictive factor was the short
history of worsening of exudation just before switching,
which increased the chances of a beneficial outcome.
Further studies will be needed to confirm our results, ideally
with a prospective design and a larger cohort.
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